PMID- 23327432
OWN - NLM
STAT- MEDLINE
DCOM- 20131204
LR  - 20220420
IS  - 1936-2692 (Electronic)
IS  - 1088-0224 (Linking)
VI  - 18
IP  - 10 Suppl
DP  - 2012 Nov
TI  - Achieving antihyperglycemic treatment goals with incretin-related therapies.
PG  - S219-27
AB  - The management of type 2 diabetes mellitus (T2DM) remains challenging. 
      Limitations associated with many current therapies include hypoglycemia and 
      weight gain. An increased understanding of the pathophysiology of T2DM has led to 
      the development of incretin-related antihyperglycemic therapies. These agents 
      enhance insulin secretion and inhibit inappropriate glucagon secretion, both in a 
      glucose-dependent manner. As a result, they can lower blood glucose levels with a 
      low risk of hypoglycemia or weight gain. Incretin-based therapies, the dipeptidyl 
      peptidase 4 inhibitors and the glucagonlike peptide-1 receptor agonists, are now 
      integrated into T2DM treatment algorithms. Trial data and clinical experience 
      have shown that these agents are efficacious and generally well tolerated.
FAU - Blonde, Lawrence
AU  - Blonde L
AD  - Ochsner Medical Center, Department of Endocrinology, Diabetes, and Metabolic 
      Diseases, 1514 Jefferson Hwy, New Orleans, LA 70121, USA. lblonde@oschsner.org
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Manag Care
JT  - The American journal of managed care
JID - 9613960
RN  - 0 (Incretins)
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Humans
MH  - Hyperglycemia/*drug therapy
MH  - Incretins/*therapeutic use
MH  - Practice Guidelines as Topic
MH  - United States
EDAT- 2013/01/25 06:00
MHDA- 2013/12/16 06:00
CRDT- 2013/01/19 06:00
PHST- 2013/01/19 06:00 [entrez]
PHST- 2013/01/25 06:00 [pubmed]
PHST- 2013/12/16 06:00 [medline]
AID - 89019 [pii]
PST - ppublish
SO  - Am J Manag Care. 2012 Nov;18(10 Suppl):S219-27.